Cluster Analysis to Identify Metabolic Syndrome Components and Physical Fitness in Patients With Metabolic Syndrome (METS)

January 23, 2024 updated by: Istanbul Galata University

A Study of Cluster Analysis to Identify Metabolic Syndrome Components and Physical Fitness in Patients With Metabolic Syndrome

The components of MetS (abdominal obesity, high blood pressure, high serum glucose, high triglyceride level and low HDL-C) differ according to demographic characteristics such as age, gender and comorbidities. Low physical activity level, genetic makeup, nutritional disorders, decreased muscle strength and low cardiorespiratory fitness can be counted among the risk factors associated with MetS. In our study, it was aimed to examine the relationship between the components of the MetS and muscle strength, physical activity, functional capacity and quality of life. Our secondary aim is to investigate the independent effects of different components of MetS on each parameter.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Detailed Description

The participants' sociodemographic characteristics such as age, height, weight, body mass index, waist circumference, marital status and education level, and anthropometric measurements, body fat percentage distributions, fasting blood glucose, HbA1c and lipid profiles will be recorded from previous analysis reports. Lower extremity quadriceps muscle strength Hand-held dynamometer, grip strength hand dynamometer, physical activity level International Physical Activity Questionnaire-Short Form-IPAQ-SF, number of steps pedometer, functional capacity 6 minute walking test and quality of life will be evaluated with the European Quality of Life Scale-5 Dimension.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Observational

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
112

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey
        • Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Department of Endocrinology and Metabolic Diseases

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

35 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Volunteers between the ages of 40-65, who have been diagnosed with MetS on the basis of type 2 diabetes for at least one year by an Internal Medicine Specialist, applying to the Department of Endocrinology and Metabolism Diseases, Department of Internal Medicine, Istanbul University, Istanbul Medical Faculty, will be included in the study.

Description

Inclusion Criteria:

  • To be diagnosed with MetS by an Internal Medicine Specialist according to NCEP-ATP III criteria
  • Finding abdominal obesity component according to TURDEP-II criteria
  • Being between the ages of 40-65
  • To be able to read and write Turkish
  • Having signed the informed consent form

Exclusion Criteria:

  • Lack of cooperation
  • Those with severe peripheral or central neurological disorders
  • Patients with uncontrolled hypertension and uncontrolled arrhythmia
  • Pregnant or breastfeeding patients
  • Those with diabetic ulcer or neuropathy
  • Chronic kidney failure (eGFR<30 ml/min)
  • Chronic liver disease (ALT/AST<3X Normal upper limit)
  • Those with serious respiratory system disease
  • Patients with cardiac pacemaker
  • History of previous stroke or myocardial infarction
  • Presence of lower and upper extremity orthopedic problems that may prevent the application of clinical tests

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Measurement of Lower Extremity Muscle Strength
Time Frame: 7 minutes.
Measurement of Lower Extremity Muscle Strength: A hand-held dynamometer will be used to evaluate quadriceps muscle strength. While the individual is in the sitting position, the arms will be crossed over the chest and the hips and knees will be flexed to 90º. Then, the individual will be asked to bring the knee to full extension and make a maximal voluntary contraction for 5 seconds against the resistance applied by the dynamometer placed on the distal part of the leg. The average value will be recorded in kg/Newton.
7 minutes.
The 6-minute walking test (6MWT)
Time Frame: 6 minutes.
Functional Capacity Measurement: The 6-minute walking test (6MWT) will be used to evaluate the functional exercise capacity of individuals. The 6MWT is a valid and reliable test, easy to administer, well tolerated, and more reflective of activities of daily living than other tests. The test will be applied according to the criteria of the American Thoracic Society (ATS). Patients will rest for at least 10 minutes before the test. They will then be asked to walk as fast as they can but without running in 6 minutes on a straight 30-meter corridor. During the test they will be encouraged to walk fast using their maximum speed. Oxygen saturation and heart rates of the patients before and after the test will be evaluated with Baseline® finger pulse oximeter, systolic and diastolic blood pressures with sphygmomanometer, dyspnea and fatigue levels will be evaluated with Modified Borg Scale. At the end of the test, the distance that patients can walk (6MWM) will be recorded in meters.
6 minutes.
Physical activity levels of individuals will be determined by IPAQ-SF scale
Time Frame: 8 minutes.
Physical activity levels of individuals will be determined by IPAQ-SF. In the study, the self-administered short form of the questionnaire, which includes "the last seven days", will be used to evaluate the level of physical activity. This short form consists of seven questions and provides information about sitting, walking, moderate-intensity activities, and time spent in vigorous activities. In addition, there is a sitting question to determine the sedentary time. However, it is not included in the scoring. Calculation of the total score of the short form includes the sum of time (minutes) and frequency (days) of walking, moderate-intensity activity, and vigorous activity. In the evaluation of all activities, the criterion is that each activity is done for at least 10 minutes at a time.
8 minutes.
Measurement of step counts by Pedometers
Time Frame: The participant's step count will be tracked for 7 days.
Step Count Measurement: Pedometers (pedometers); It is a portable, easy-to-use tool that can objectively measure the number of steps, kilometers walked, and is used to evaluate the level of daily physical activity. It is a sensor sensitive to mechanical movement during walking. Pedometers have been shown to be the most valid method for evaluating step counts. The individuals participating in our study will be introduced to the OMRON branded Walking style One 2.1 pedometer device, validated by De Craemer et al., and will be taught to use it. Then, individuals will be asked to carry this pedometer all day for a week, in the waist area or in the pocket. The pedometer used has the feature of recording the number of steps, energy expenditure level (kcal) and the time spent with active movement with its 3D sensor, 7-day retrospective memory. After one week of use, the data recorded with the pedometer will be taken.
The participant's step count will be tracked for 7 days.
Grip Strength Measurement
Time Frame: 5 minutes.
Grip Strength Measurement: A Jamar brand hydraulic type dynamometer will be used to measure the grip strength of the participants. It will be performed with the individual in a sitting position on an unsupported chair, shoulder adduction, elbow 90º flexion, forearm in neutral position, wrist in 0-30° extension and 0-15° ulnar deviation. Participants will be asked to squeeze the dynamometer with maximum effort for 5 seconds with their dominant hand and then leave it completely relaxed. The average of the obtained values will be recorded in "pounds".
5 minutes.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Istanbul Galata University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
June 13, 2022

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 27, 2022

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 27, 2023

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 24, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 5, 2022

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 6, 2022

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 24, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 23, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
June 1, 2022

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • IstanbulGalataUni

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings